OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Harding on the Prevalence of TSC1/2 Mutations in GI Cancer

February 22nd 2023

James J. Harding, MD, discusses the prevalence of TSC1 and TSC2 mutations in gastrointestinal cancer, and the need to develop a standard-of-care treatment for patients with these genetic alterations.

Dr. Blackwood on the Implementation of the I SPY2 Trial in Breast Cancer

February 22nd 2023

M. Michele Blackwood, MD, FACS, discusses the implementation of the phase 2 I-SPY 2 trial in breast cancer at Robert Wood Johnson Medical Center.

Dr. Zhang on the Use of PARP Inhibitor–based Combinations in mCRPC

February 21st 2023

Tian Zhang, MD, MHS, discusses the use of PARP inhibitor–based combinations in patients with metastatic castration-resistant prostate cancer.

Dr. Ramnaraign on the Investigation of Atezolizumab Plus Tivozanib in CRPC

February 20th 2023

Brian Ramnaraign, MD, discusses the investigation of atezolizumab with tivozanib in castrate-resistant prostate cancer.

Dr. Roy on the Effect of Neoadjuvant Chemotherapy on OS in Sarcomatoid Bladder Cancer

February 20th 2023

Arya Mariam Roy, MBBS, discusses the effect of neoadjuvant chemotherapy on overall survival in patients with sarcomatoid muscle-invasive bladder cancer.

Dr. McGregor on Cabozantinib Plus Atezolizumab in Non–Clear Cell RCC

February 20th 2023

Bradley McGregor, MD, discusses the investigation of cabozantinib plus atezolizumab in patients with non–clear cell renal cell carcinoma.

Dr. Bamias on Final Analysis of Atezolizumab Monotherapy in the IMvigor130 Trial in mUC

February 18th 2023

Aristotelis Bamias, MD, discusses key efficacy data from a final analysis of the phase 3 IMvigor130 trial in metastatic urothelial carcinoma.

Dr. Albigès on the CaboPoint Trial in Advanced RCC

February 18th 2023

Laurence Albigès, MD, PhD, discusses the main objective and trial design of the phase 2 CaboPoint study in renal cell carcinoma, as well as key efficacy and safety data reported in an interim analysis of this study.

Dr. Gulhati on Current Treatment Approaches in Pancreatic Cancer

February 18th 2023

Prateek Gulhati, MD, PhD, discusses current treatment approaches in pancreatic cancer and strategies under investigation within the space.

Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple Myeloma

February 18th 2023

Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.

Dr. Srour on Orca-Q Transplantation in Hematologic Malignancies

February 18th 2023

Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.

Dr. Aggarwal on Characteristics Associated With PSA PFS from the PRESTO Trial in Prostate Cancer

February 17th 2023

Rahul Aggarwal, MD, discusses the association between baseline characteristics and prostate-specific antigen progression-free survival in patients with high-risk biochemically relapsed prostate cancer from the phase 3 PRESTO trial.

Dr. Agarwal on the Efficacy of Talazoparib Plus Enzalutamide in First-line mCRPC

February 17th 2023

Neeraj Agarwal, MD, discusses the efficacy of talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.

Dr. Frank on CD22 CAR T-cell Therapy in Relapsed LBCL

February 17th 2023

Matthew Frank, MD, PhD, discusses findings from a single-institution phase 1 trial investigating autologous CAR T cells targeting CD22 in adults with large B-cell lymphoma, including those who relapse after or are refractory to CD19-directed CAR T-cell therapy.

Dr. Galsky on Updated Findings From the CheckMate-274 Trial in Urothelial Cancer

February 17th 2023

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.

Dr. Necchi on Key Results From Cohort B of the KEYNOTE-057 Trial in MIBC

February 17th 2023

Andrea Necchi, MD, discusses updated analysis of cohort B in the phase 2 KEYNOTE-057 trial in non-muscle invasive bladder cancer.

Dr. Hadaschik on Treatment After Apalutamide Progression in SPARTAN Trial

February 16th 2023

Boris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.

Dr. Narkhede on Siltuximab for CRS and ICANS in Hematologic Malignancies

February 16th 2023

Mayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.

Dr. Tombal on the OS Benefit of Darolutamide Plus ADT/Docetaxel in mHSPC

February 16th 2023

Bertrand Tombal, MD, PhD, discusses the overall survival benefit associated with androgen-deprivation therapy plus darolutamide in metastatic hormone-sensitive prostate cancer.

Dr. Haddad on the Effect of Anastrozole on Endocrine Suppression in ER+/HER2- Breast Cancer

February 16th 2023

Tufia C. Haddad, MD, discusses key results from a prospective trial on adjuvant anastrozole in estrogen receptor–positive, HER2-negative breast cancer.